Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio is poised for success with its promising pipeline, particularly the company's lead candidate PBFT02, which targets the critical underlying pathology of neurodegenerative diseases. However, regulatory hurdles may pose a challenge for the company, as evidenced by Eli Lilly's discontinuation of a similar program earlier this year due to a lack of efficacy in patients. As such, investors should closely monitor the company's advancements in clinical trials and regulatory approvals.

Bears say

Passage Bio is a clinical-stage company with limited revenue from licensing and royalties and only $46.3 million in cash at the end of FY25, which may not be enough to support their gene therapy development and commercialization efforts. Additionally, there are clinical and competitive risks that may hinder the success of their lead program PBFT02 for frontotemporal dementia, as well as the standard risks in the biotech industry. These factors, combined with the overall uncertain future of gene therapy, contribute to a negative outlook on Passage Bio's stock.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of Jun 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.